vTv Therapeutics Inc. 8-K

What Happened

• vTv Therapeutics Inc. filed an 8-K on June 29, 2026 reporting the results of its Annual Meeting held June 26, 2026. Stockholders elected the company’s director nominees, ratified Ernst & Young LLP as independent auditor for fiscal 2026, and voted on a nonbinding advisory proposal regarding executive compensation.
• The company reported the vote totals for each nominee and each proposal in the filing; the report was signed by Michael Tung, Executive Vice President and Chief Financial Officer.

Key Details

• Director elections (For / Withheld; broker non-votes: 310,535):
  • Srinivas Akkaraju: 720,963 For, 1,938,192 Withheld
  • Raymond Cheong: 729,489 For, 1,929,666 Withheld
  • Fahed Al Marzooqi: 2,395,229 For, 263,926 Withheld
  • Richard S. Nelson: 2,395,013 For, 264,142 Withheld
  • Anne Phillips: 905,938 For, 1,753,217 Withheld
  • Paul Sekhri: 905,325 For, 1,753,830 Withheld
  • Daniel K. Spiegelman: 774,244 For, 1,884,911 Withheld
• Auditor ratification: Ernst & Young LLP was ratified for the fiscal year ending December 31, 2026 (2,964,869 For; 1,952 Against; 2,869 Abstain).
• Advisory vote on executive compensation (nonbinding): 686,535 For; 5,291 Against; 1,967,329 Abstain (broker non-votes: 310,535).

Why It Matters

• Director elections determine who will oversee company strategy and governance through the next year; the filing provides precise vote tallies that investors can use to gauge shareholder support for board members.
• Auditor ratification confirms Ernst & Young LLP will audit vTv’s financial statements for fiscal 2026, an important element of financial reporting reliability.
• The nonbinding executive compensation vote shows limited affirmative support and a large number of abstentions, which management may consider when communicating with investors about pay practices.